|
US9012141B2
(en)
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
|
KR101173871B1
(ko)
*
|
2003-02-06 |
2012-08-16 |
앤저 테라퓨틱스 인코퍼레이티드 |
변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
|
|
US7695725B2
(en)
*
|
2003-02-06 |
2010-04-13 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
KR101192652B1
(ko)
|
2003-02-06 |
2012-10-19 |
앤저 테라퓨틱스 인코퍼레이티드 |
비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
|
|
WO2004091375A2
(en)
*
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Epha2 and non-neoplastic hyperproliferative cell disorders
|
|
US7842289B2
(en)
|
2003-12-24 |
2010-11-30 |
Aduro Biotech |
Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
|
|
US7612162B2
(en)
*
|
2004-09-21 |
2009-11-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
|
|
CA2584130A1
(en)
*
|
2004-10-18 |
2006-04-27 |
Medimmune, Inc. |
High cell density process for growth of listeria
|
|
WO2006047638A2
(en)
*
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
|
|
DE102006004612A1
(de)
*
|
2006-02-01 |
2007-08-16 |
Ralf Dr. med. Jochem |
Therapeutische Zusammensetzung zur Vorbeugung und Bekämpfung von Knochenmetastasen
|
|
US7935804B2
(en)
|
2006-03-01 |
2011-05-03 |
Aduro Biotech |
Engineered Listeria and methods of use thereof
|
|
EP2860253B1
(en)
|
2006-03-01 |
2018-08-01 |
Aduro Biotech, Inc. |
Engineered listeria and methods of use thereof
|
|
US20070207171A1
(en)
*
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
|
WO2007103261A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Medimmune, Inc. |
Listeria-based epha2 immunogenic compositions
|
|
US8926993B2
(en)
*
|
2006-07-17 |
2015-01-06 |
Aduro Biotech |
Methods and compositions using Listeria for enhancing immunogenicity by prime boost
|
|
US8268326B2
(en)
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
|
EP3284478A1
(en)
*
|
2006-08-15 |
2018-02-21 |
The Trustees of the University of Pennsylvania |
Compositions comprising hmw-maa and fragments thereof for treating cancer
|
|
BRPI0816094A2
(pt)
|
2007-08-30 |
2015-03-03 |
Daiichi Sankyo Co Ltd |
Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
|
|
WO2009044272A2
(en)
*
|
2007-10-04 |
2009-04-09 |
000'npt Mbp Gormezis' |
Laser-based vaccine adjuvants
|
|
US20140234370A1
(en)
*
|
2009-11-11 |
2014-08-21 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
|
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
|
US9017660B2
(en)
*
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
EP2283112B1
(en)
|
2008-05-19 |
2016-10-12 |
Aduro Biotech |
Compositions comprising prfa*mutant listeria and methods of use thereof
|
|
WO2010071769A2
(en)
*
|
2008-12-12 |
2010-06-24 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Chimeric l. monocytogens in1b protein
|
|
WO2010102140A1
(en)
*
|
2009-03-04 |
2010-09-10 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising angiogenic factors and methods of use thereof
|
|
US10016617B2
(en)
*
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
JP5985397B2
(ja)
*
|
2009-11-11 |
2016-09-06 |
アドバクシス インコーポレイテッド |
組換えリステリア株およびそれを含む免疫原性組成物
|
|
EP2542696B1
(en)
|
2010-03-01 |
2016-09-28 |
Caris Life Sciences Switzerland Holdings GmbH |
Biomarkers for theranostics
|
|
JP2013526852A
(ja)
|
2010-04-06 |
2013-06-27 |
カリス ライフ サイエンシズ ルクセンブルク ホールディングス |
疾患に対する循環バイオマーカー
|
|
JP5977737B2
(ja)
|
2010-05-23 |
2016-08-24 |
アデュロ バイオテック |
癌の補助薬物療法でリステリアを使用する方法および組成物
|
|
GB2482536B
(en)
|
2010-08-05 |
2013-07-24 |
Hera Pharmaceuticals Inc |
Expression of antibody or a fragment thereof in lactobacillus
|
|
CA2809362C
(en)
*
|
2010-08-24 |
2020-03-10 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn |
Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
|
|
EP2446895A1
(en)
*
|
2010-10-01 |
2012-05-02 |
Stemgen S.P.A. |
EPH receptor expression in tumor stem cells
|
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
CA2829960A1
(en)
|
2011-03-11 |
2012-09-20 |
John Rothman |
Listeria-based adjuvants
|
|
CA2850668A1
(en)
|
2011-10-04 |
2013-04-11 |
Expression Pathology, Inc. |
Srm/mrm assay for the ephrin type-a receptor 2 protein
|
|
WO2013138337A1
(en)
|
2012-03-12 |
2013-09-19 |
Advaxis |
Suppressor cell function inhibition following listeria vaccine treatment
|
|
CA3183703A1
(en)
|
2012-05-16 |
2013-11-21 |
Stemline Therapeutics, Inc. |
Cancer stem cell targeted cancer vaccines
|
|
EP2858722B8
(en)
|
2012-06-08 |
2018-02-21 |
Aduro BioTech, Inc. |
Compostions and methods for cancer immunotherapy
|
|
KR20150084033A
(ko)
|
2012-11-06 |
2015-07-21 |
아두로 바이오테크, 인코포레이티드 |
조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
|
|
US9695212B2
(en)
|
2012-12-13 |
2017-07-04 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
SG10201700916SA
(en)
|
2012-12-27 |
2017-03-30 |
Aduro Biotech Inc |
Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
PE20160080A1
(es)
|
2013-05-18 |
2016-02-21 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
SG11201609135VA
(en)
*
|
2014-05-02 |
2016-11-29 |
Univ Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
|
|
WO2016061115A1
(en)
|
2014-10-13 |
2016-04-21 |
Providence Health & Services-Oregon D/B/A Providence Portland Medical Center |
Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
|
|
CN107429289A
(zh)
*
|
2014-10-14 |
2017-12-01 |
宾夕法尼亚大学理事会 |
用于癌症治疗的联合疗法
|
|
WO2016073381A1
(en)
|
2014-11-03 |
2016-05-12 |
Cerus Corporation |
Compositions and methods for improved car-t cell therapies
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
EP3313418B1
(en)
|
2015-06-26 |
2024-03-13 |
Cerus Corporation |
Cryoprecipitate compositions and methods of preparation thereof
|
|
CA3003097A1
(en)
|
2015-10-23 |
2017-04-27 |
Cerus Corporation |
Plasma compositions and methods of use thereof
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US20190369087A1
(en)
|
2016-12-23 |
2019-12-05 |
Cerus Corporation |
Systems and methods for testing and screening using compound bound substrates
|
|
CA3055203A1
(en)
|
2017-03-03 |
2018-09-07 |
Cerus Corporation |
Kits and methods for preparing pathogen-inactivated platelet compositions
|
|
AU2018395525B2
(en)
|
2017-12-29 |
2023-09-14 |
Cerus Corporation |
Systems and methods for treating biological fluids
|
|
JP7571063B2
(ja)
|
2019-06-22 |
2024-10-22 |
シーラス コーポレイション |
生物学的流体の処理を実施するシステム及び方法
|
|
US12011510B2
(en)
|
2019-06-22 |
2024-06-18 |
Cerus Corporation |
Biological fluid treatment systems
|
|
CN114269394A
(zh)
|
2019-06-28 |
2022-04-01 |
塞鲁斯公司 |
用于实现生物流体处理装置的系统和方法
|
|
CN114015644A
(zh)
*
|
2021-11-05 |
2022-02-08 |
成都生物制品研究所有限责任公司 |
一种单一病毒收获液的生产方法
|
|
CN114848654B
(zh)
*
|
2022-04-18 |
2024-04-05 |
武汉大学 |
阿司匹林在制备用于引起肿瘤免疫原性细胞死亡的药物中的应用
|